Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

Clinical Trials

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction